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Background: Individuals with neovascular age-related macular degeneration (AMD) have 
altered number and distribution of retinal macrophages and show changes in circulating 
antibodies. We wanted to investigate the corresponding precursors, with subpopulations. 
We therefore measured monocyte and B-lymphocyte populations in individuals with neovas-
cular AMD.
Design: This was an observational case–control study.
Participants or samples: A total of 31 individuals with neovascular AMD and 30 healthy 
age-matched controls were included.
Methods: Patients and controls were interviewed, and ophthalmological examination included 
visual acuity assessment using the Early Treatment Diabetic Retinopathy Study (ETDRS) chart, 
spectral domain optical coherence tomography (SD-OCT), slit-lamp examination and fundus 
photography. Moreover, venous blood was drawn and prepared for flow cytometry. Cells were 
gated and measured for surface markers.
Main outcome measures: Relative amounts of monocytes and B-lymphocytes with subsets, 
as well as selected surface markers, were measured.
Results: The two groups did not significantly differ in age, smoking history, body mass index, 
physical activity or C-reactive protein (CRP). Total monocytes (percentage of all leukocytes) 
were lower in the neovascular AMD group (median 5.5%) compared with the level in the control 
group (6.5%; P-value: 0.028). The percentage of intermediate monocytes positive for cluster 
of differentiation 11b (CD11b) was lower for AMD patients (99.4%) compared with 100% for 
the control group (P-value: 0.032).
Conclusion: We observed lower numbers of monocytes, which show a potentially impaired 
ability to migrate across the endothelial wall in patients with neovascular AMD. These subtle 
changes could potentially lead to an imbalance in the recruitment of macrophages into the retina 
during disease development.
Keywords: macular degeneration, choroidal neovascularization, flow cytometry
Introduction
Age-related macular degeneration (AMD) is the leading cause of vision impairment 
globally, but the cause of the disease is still unknown. The role of the immune system 
in AMD pathogenesis is currently under investigation by several groups, and a previous 
study has reported the potentially important role of monocytes in AMD pathogenesis, 
even though the role of both resident macrophages and peripheral monocytes is still 
not known.1
The peripheral monocyte population is functionally divided into three subtypes of 
monocytes: classical monocytes (cluster of differentiation [CD]14++CD16-), gener-
ally considered scavenger cells; intermediate monocytes (CD14++CD16+), which are 
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involved in angiogenesis and formation of reactive oxygen 
species; and nonclassical monocytes (CD14+CD16++), 
which are considered proinflammatory cells.2 Functionally, 
the classical and intermediate monocytes are more phagocytic 
than nonclassical monocytes. Distinct roles of the different 
monocyte subsets in human disease have been suggested, 
with CD16+ monocytes playing a role in autoimmune and 
chronic inflammatory diseases such as diabetes and obesity.3 
AMD is clearly a disease of the elderly; hence, the effect of 
aging on monocyte function could be important in AMD. 
Overall, there seems to be a tendency toward impaired 
ability by monocytes to phagocytize in the elderly.4 This 
decrease in phagocytic ability could theoretically result 
in increased debris accumulation in the retina, leading to 
parainflammation.
The role of B-lymphocytes has not previously been 
studied in relation to AMD, but it has been suggested that 
antiretinal antibodies may play a role in the etiology of AMD.5 
B-lymphocytes are circulating cells that, when activated, can 
turn into plasma cells. Plasma cells are mostly concentrated in 
the lymphoid tissue and the spleen, where they produce large 
quantities of antibodies, which are released into the circula-
tion. It is known that the B-lymphocyte population changes 
with age.6,7 This could be due to increased autoimmunity 
seen in the aged population. Furthermore, mammalian naïve 
B-lymphocytes express a complement factor H-like protein 
that has similar properties as factor H, a part of the comple-
ment cascade known to affect the development of AMD.8,9
Therefore, we wanted to study the monocyte and B- 
lymphocyte populations in patients with neovascular AMD and 
compare our findings with healthy, age matched controls.
Methods
Design, setting and participants
During a 10-month period, we included 61 participants in this 
case–control study. All participants were more than 70 years 
of age and nonsmokers. Patients with AMD (n=31) typically 
were asked to participate during their regular assessment vis-
its. Most patients were included during ongoing anti-vascular 
endothelial growth factor (VEGF) treatment, but none had 
received ranibizumab or aflibercept within 4 or 8 weeks 
respectively. All patients had previously been diagnosed 
with neovascular AMD by a medical retinal specialist using 
fluorescein and indocyanine green angiography, spectral 
domain optical coherence tomography (SD-OCT) and clinical 
examination. We also asked relatives as well as patients who 
arrived at the department for reasons other than retina-related 
illness to participate as a control group (n=30).
interview, examination and sampling
Participants were asked if they had other somatic illnesses 
and were more specifically asked if they currently suffer or 
had suffered from hypertension, coronary disease, diabetes or 
known renal insufficiency. Thereafter, all medications were 
recorded and participants were asked if they had any signs 
of ongoing infection. We also recorded alcohol and tobacco 
consumption. Weight and height were recorded to calculate 
body mass index (BMI). Finally, participants were asked if 
they currently participated in any regular activity to improve 
or maintain their physical activity.
Visual acuity of all participants was measured using the 
Early Treatment Diabetic Retinopathy Study (ETDRS) chart. 
To assess retinal pathology, we scanned all participants with 
SD-OCT, and for control participants, we also performed 
fundus photography.
Finally, we collected two tubes of venous blood. The first 
tube was of 3 mL capacity and contained lithium-heparin gel 
for measuring C-reactive protein (CRP). The second tube 
measured 5 mL and contained ethylenediaminetetraacetic 
acid (EDTA) for flow cytometry. Analysis was performed 
within 4 hours of phlebotomy.
exclusion
We excluded control participants who had dry AMD or any 
participants who had a CRP level greater than 22 mg/L or 
symptoms of infectious disease. We also excluded individu-
als who took medications that significantly influenced the 
immune system such as methotrexate and prednisolone. 
Individuals suffering from chronic inflammation as well as 
smokers or passive smokers were also excluded.
Flow cytometry
For flow cytometry, the white blood cell (WBC) count was 
determined using the Sysmex XE-5000 hematology analyzer 
(Sysmex Corporation, Kobe, Japan). A volume corresponding 
to 10×106 cells was transferred to a 50 mL polypropylene tube. 
The erythrocytes in the sample were lysed using Red Blood 
Cell Lysis Buffer, which was afterward removed by washing 
and centrifuging three times. The samples were centrifuged at 
500× g for 5 minutes at every washing cycle. A solution corre-
sponding to 500,000 cells was transferred to four test tubes and 
was incubated together with suitable amounts of fluorochrome-
conjugated antibody combinations. Negative isotope control 
panels were used to correct for unspecific binding. Flow cytom-
etry was performed within 4 hours of sampling. The Canto II 
was used to record all lymphocytic events (identified by forward/
side scatter) over a period of 3 minutes for every tube.
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Monocytes were identified by forward/side scatter and 
divided into subgroups using CD14 (BioLegend clone: 
hcd14) and CD16 (BioLegend clone: B73.1) (Figure 1). 
Classical monocytes were defined as CD14++ and CD16-. 
Nonclassical monocytes were identified as CD14+, CD16++ 
and intermediate ones as CD14++ and CD16+. As the 
three subsets seem to have different physiological func-
tions, we wanted to study the expression of molecules for 
cell–cell communication on their surface, their ability to 
activate other leukocytes and molecules for penetrating 
the capillary walls and their capacity for migration to the 
surrounding tissue. For cell–cell communication, we chose 
CD11a (BioLegend Clone: HI111) and CD162 (BioLegend 
Clone: KPL-1). Furthermore CD63 (BioLegend Clone: 
H5C6), CD66B (BioLegend Clone: G10F5) and CD182 
(BioLegend Clone: 5E8/CXCR2) were used as markers for 
the monocyte population’s ability to activate neutrophils and 
platelets. CD62L (BioLegend Clone: DREG-56) and CD162 
(BioLegend Clone: KPL-1) are both involved in leukocyte 
rolling on activated endothelium. CD11B (BioLegend 
Clone: ICRF44), CD31 (BioLegend Clone: WM59) and 
CD54 (BioLegend Clone: HA58) are associated with the 
transport of leukocytes across the endothelium and out into 
the inflamed tissue.
To identify B-lymphocytes, all lymphocytes in the 
forward/side scatter were selected and only CD19 (BioLe-
gend Clone: HIB19)-positive cells were singled out for 
further characterization. To study the abundance of dif-
ferent subtypes of B-lymphocytes, we chose regulatory 
B-lymphocytes (B-regs), naïve B-lymphocytes and memory 
B-lymphocytes. B-regs were defined as CD19+ (BioLegend 
Clone: HIB19) CD24+ (BioLegend Clone: ML5) CD38+ 
(BioLegend Clone: HB-7), naïve B-lymphocytes as CD19+ 
CD10- (BioLegend Clone: HI10a) CD27- (BioLegend 
Clone: M-T271) CD38- and memory B-lymphocytes as 
CD19+ CD10- CD27+ CD38-. A novel subgroup of 
B-lymphocytes called aging B-cells (ABCs) was identified as 
CD19+ CD11c+ (BioLegend Clone. 3.9) CD21- (BioLegend 
Clone: Bu32).
statistical analyses
Sample size power calculations using a significance level of 
0.05 and a power of 80% suggested that at least 26 individu-
als needed to be included in each group. Statistical analyses 
were performed using IBM SPSS Statistics version 19. 
Independent-samples Mann–Whitney U test was used for 
continuous variables and Pearson chi-squared test was used 
for categorical values.
ethics, consent and permissions
After receiving written and verbal information about the 
purpose and execution of the study, all participants signed 
a consent form. They were informed of their right to with-
draw at any point. The study was approved by the Regional 
Committee of Ethics in Research of the Region of Zealand 
(SJ-142).
Results
Baseline characteristics of patients and healthy individu-
als are shown in Table 1. Sixty-three individuals agreed to 
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Figure 1 gating strategies for monocytes and subgroups.
Notes: (a) nonclassical monocytes; (b) intermediate monocytes; (c) classical monocytes.
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participate in the study. Two individuals in the control group 
were excluded because they were found to have dry AMD, 
leaving 31 in the neovascular AMD group and 30 in the 
control group. The neovascular group consisted of ten males 
and 21 females, and the control group consisted of 16 males 
and 14 females. This difference was not significant. The two 
groups did not differ significantly in age, BMI, smoking 
history, alcohol intake, physical activity or CRP, as well as 
in the WBC count.
The neovascular AMD group had significantly lower rela-
tive amounts of monocytes compared with the control group, 
because among all leukocytes, only 5.5% were monocytes 
in the neovascular AMD group, compared with 6.5% in the 
control group (P=0.028). To further investigate whether the 
lower number of monocytes could be attributed to a certain 
subtype of monocytes, we studied the distribution of clas-
sical monocytes, intermediate monocytes and nonclassical 
monocytes (Figure 1). We found no differences between 
patients with AMD and healthy controls (Table 2), suggesting 
that the observed difference is due to a general decrease in 
the relative number of monocytes rather than a decline in a 
specific subgroup.
The expression of CD200 on CD11b+ monocytes has pre-
viously been reported to be increased in patients with AMD.1 
Therefore, we studied a spectrum of recruitment molecules 
appearing on the subgroups of monocytes. We found that 
CD11b on intermediate monocytes was significantly reduced 
in the neovascular AMD group (P,0.032), while no other 
significant differences were observed (Table 3).
In AMD, circulating B-cells have not been studied 
before, despite the previously described circulating retinal 
autoantibodies in patients with AMD.5 In addition, a new 
subpopulation of B-cells, ABCs, has been discovered and we 
therefore wanted to study the distribution of B-lymphocytes 
and, in particular, the ABC population in AMD. However, no 
Table 1 Population characteristics
Characteristics Patients with 
AMD (n=31)
Control 
individuals 
(n=30)
P-value
age, years, mean (sD) 79.7 (6.0) 77.2 (6.5) 0.131§
Males, n (%) 10 (32) 16 (53) 0.096#
BMi, kg/m2, mean (sD) 26.6 (5.1) 25.9 (4.6) 0.555§
Previous smoker, n (%) 16 (52) 16 (53) 0.893#
excessive alcohol use, n (%) 7 (23) 8 (27) 0.711#
Physically active, n (%) 9 (29) 7 (23) 0.613#
CrP level, mg/l, n (%)† 0.270#
,3.1 20 (67) 24 (83)
3.1–8.0 8 (27) 3 (10)
.8.0 2 (7) 2 (7)
White blood cells,  
in ×109 cells/l, mean (sD)‡
6.4 (1.6) 6.1 (1.3) 0.430§
Notes: §independent samples t-test; #χ2 test; †data missing for one patient with 
aMD and one control individual; ‡data missing for one patient with aMD and three 
control individuals.
Abbreviations: aMD, age-related macular degeneration; BMi, body mass index; 
CrP, C-reactive protein.
Table 2 Total monocytes and subpopulation distribution of 
monocytes, expressed as percentage (interquartile range)
Population of cells Patients with 
AMD 
Control 
individuals
P-value§
Total monocytes† 5.5 (4.3–6.5) 6.5 (5.3–7.3) 0.028
Classical monocytes‡ 68.5 (60.8–71.1) 69.4 (66.8–75.9) 0.509
intermediate monocytes‡ 5.1 (3.1–7.2) 5.0 (3.0–7.1) 0.088
nonclassical monocytes‡ 9.6 (5.5–12.1) 8.8 (6.3–11.6) 0.900
Notes: §Mann–Whitney U test; †percentage of total leukocytes; ‡percentage of total 
monocytes.
Abbreviation: aMD, age-related macular degeneration.
Table 3 recruitment molecules on subpopulation of 
monocytes, expressed as median percentage positive for marker 
(interquartile range)
Cell 
population
Marker Patients with 
AMD
Control 
individuals
P-value§
Classical 
monocytes
CD11a 100 (100–100) 100 (100–100) 1.000
CD11b 98.6 (94.6–99.9) 99.4 (95.1–99.9) 0.432
CD62l 19.2 (3.6–53.5) 19.4 (6.0–70.3) 0.501
CD54 99.5 (97.8–99.8) 99.5 (98.5–99.8) 0.896
CD162 100 (100–100) 100 (100–100) 1.000
intermediate 
monocytes
CD11a 100 (100–100) 100 (100–100) 0.317
CD11b 99.4 (97.7–100) 100 (99.5–100) 0.032
CD62l 15.9 (8.7–34.7) 13.0 (5.1–42.6) 0.971
CD54 100 (99.2–100) 99.9 (99.4–100) 0.871
CD162 100 (100–100) 100 (100–100) 0.325
nonclassical 
monocytes
CD11a 100 (100–100) 100 (100–100) 0.317
CD11b 41.9 (34.9–54.3) 48.0 (32.9–58.5) 0.363
CD62l 1.6 (0.9–3.0) 5.0 (0.9–8.6) 0.152
CD54 98.8 (98.1–99.6) 98.8 (97.2–99.3) 0.773
CD162 100 (100–100) 100 (100–100) 0.309
Note: §Mann–Whitney U test. Bold values are statistically significant.
Abbreviations: aMD, age-related macular degeneration; CD, cluster of 
differentiation.
Table 4 B-lymphocytes and subgroups, expressed as median 
percentage (interquartile range)
Population of cells Patients with 
AMD 
Control 
individuals
P-value§
Total B-lymphocytes† 6.7 (4.9–9.8) 6.1 (4.5–9.7) 0.603
Memory B-lymphocytes‡ 13.4 (7.9–27.3) 18.6 (12.2–26.0) 0.327
naïve B-lymphocytes‡ 65.3 (49.9–77.9) 58.7 (52.1–70.4) 0.367
regulatory B-lymphocytes‡ 50.7 (41.7–68.1) 45.6 (36.5–58.4) 0.103
aging B-lymphocytes‡ 1.0 (0.4–1.8) 1.5 (0.8–3.5) 0.132
Notes: §Mann–Whitney U test; †percentage of total lymphocytes; ‡percentage of 
total B-lymphocytes.
Abbreviation: aMD, age-related macular degeneration.
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significant differences in the distribution of B-lymphocytes 
between the two groups were found (Table 4).
Discussion
In a postmortem study, Lad et al showed that patients with 
AMD had a significantly higher number of retinal mac-
rophages within the macula compared with controls.10 The 
macrophages were also morphologically different in the two 
groups and some were shown to be bone marrow-derived 
macrophages. The mechanism behind this accumulation is 
not known, but it is hypothesized that oxidative stress causes 
impairment in the retina’s ability to repair damaged tissue.11 
This leads to accumulation of amyloid-β and other waste 
products, as well as the formation of drusen. As a result, 
the retinal pigment epithelium (RPE) is damaged due to 
inflammation around the growing drusen. A damaged RPE, 
together with normal aging, leads to the thickening of Bruch’s 
membrane and the subsequent breakdown of the blood–
retina barrier, exposing the retina to the peripheral immune 
system. When circulating monocytes migrate over to retinal 
tissue, they change into macrophages, phagocytotic cells.1 
Parainflammation, together with the recruitment of peripheral 
monocytes, orchestrates a proinflammatory environment, 
ultimately leading to the production of VEGF, resulting in 
choroidal neovascularization (CNV) and growth.11 This sug-
gested that peripheral changes could potentially be important 
in AMD pathogenesis, and previous studies have shown 
specific profiles of monocytes in patients with AMD.12
Indeed, after experimentally induced CNV in mice, it 
has been shown that bone marrow-derived macrophages 
migrate to the retina from the peripheral circulation.13 But 
their role in relation to CNV is debated. The diameter and 
thickness of the CNV was significantly smaller in mice that 
did not have a normal monocyte population, the precursors 
to macrophages.14
On the other hand, intraocular injection of macrophages 
from young experimental animals, into old animals, pro-
tected the retina from the occurrence of CNV. Injection of 
macrophages from older animals did not have a protective 
effect.15 There are two main types of macrophages. M1 are 
proinflammatory and are tumor suppressors. M2 are stimu-
lated by interleukin (IL)-10, are mostly anti-inflammatory 
and stimulate the development of new vessels and remodel-
ing of tissue.16
As mentioned earlier, monocytes can be divided into 
functional subgroups. Classical monocytes are CD16 dim 
and produce the majority of reactive oxygen; these seem to 
be specialized in protection against microbial attacks.17 The 
intermediate subset is highly activated and is functionally not 
a mix of classical and nonclassical monocytes. Nonclassical 
and intermediate monocytes are associated with chronic 
inflammation in an aging population and may leave the 
elderly with impaired ability for phagocytosis. The nonclassi-
cal monocytes are thought to have a patrolling function.18,19
We have previously reported on the frequency of the 
different monocyte subtypes in AMD using the chemokine 
receptors CCR2 and CX3CR1.20 No differences were 
observed among the different groups of patients.20 Our cur-
rent results are in agreement with this finding using the CD16 
molecule for monocyte subtype distinction. If our results can 
be confirmed in future studies, it may indicate that patients 
with AMD have a lower absolute number of monocytes, with 
no changes in the relative distribution. A lower number of 
monocytes that have an impaired ability to travel across the 
endothelium may induce neovascularization in individuals 
who develop wet AMD.
The intermediate subset of monocytes is more effective at 
antigen presentation and they express more CD11b than other 
monocytes, which also indicates a higher level of activation. 
CD11b is involved in transendothelial migration.18 Perivas-
cular resident retinal macrophages express CD11b, and if 
CD11b is blocked experimentally, macrophages are pre-
vented from being recruited over activated endothelium.21
Individuals with AMD in our study showed lower levels 
of total monocytes and the intermediate subset expressed 
lower levels of the recruitment molecule CD11b. Individu-
als with AMD do not seem to have the ability to clear waste 
products efficiently from tissues, such as the retina, and may 
therefore be more prone to develop drusen. A recent study 
also found an increased number of CD11b+ cells in the 
peripheral blood of patients with AMD.22 Curiously, we also 
found that the CD200 molecule – a regulator of microglial 
activity – on CD11+ monocytes, was increased in patients 
with AMD compared to controls, suggesting the notion of 
an important role for CD11 in AMD pathogenesis.1
Even though retinal autoantibodies have been detected 
systemically in patients with AMD, the role of B-cells has 
not been studied in AMD.5 This is probably mostly due to 
the focus on the innate immune system in AMD pathogenesis 
but also because knowledge of the ABCs has been evolving 
slowly. Currently, the B-lymphocytes can be divided into 
regulatory B-lymphocytes (B-regs), naïve B-lymphocytes, 
memory B-lymphocytes and a novel subgroup called aging 
B-cells (ABCs).7 The role of the different B-cells in aging and 
disease remains to be clarified. B-cells are mostly involved in 
autoimmune diseases and ABCs seem to increase in numbers 
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in aging patients with known autoimmune disease. Because 
AMD, as such, is not considered an autoimmune disease, it is 
not surprising that we do not detect any differences between 
patients and healthy individuals.
The number of participants in this study is relatively 
small, and we only gathered data from one visit for each 
participant. In addition, even though our findings may be 
statistically significant, a potential biological relevance needs 
to be further investigated because the observed differences 
are small.
Conclusion
We found that the absolute number of monocytes is dimin-
ished in patients with neovascular AMD, and in particular, 
we found lower levels of expression of the CD11b molecule 
on intermediate monocytes, suggesting a potential role for 
this molecule in disease development.
Disclosure
The authors report no conflicts of interest in this work.
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